Peré Domingo

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

François Raffi, Hans Jaeger, Eugenia Quirós-Roldán et al. · The Lancet Infectious Diseases · 2013 · 370 citations

Treatment And Prevention, Human Retrovirus, Clinical Trials +8

Clinical utility of HIV-1 genotyping and expert advice: the Havana trial

Cristina Tural, Christopher Holtzer, Jonathan Schapiro et al. · AIDS · 2002 · 312 citations

Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection

Estebán Martínez, Juan A. Arnaiz, Daniel Podzamczer et al. · New England Journal of Medicine · 2003 · 293 citations · Full text

Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1–Infected Adults: 48-Week Results From the ASSERT Study

Frank A. Post, Graeme Moyle, Hans Jürgen Stellbrink et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2010 · 217 citations

A Randomized Trial of the Discontinuation of Primary and Secondary Prophylaxis against<i>Pneumocystis carinii</i>Pneumonia after Highly Active Antiretroviral Therapy in Patients with HIV Infection

Juan Carlos López Bernaldo de Quirós, José M. Miró, José M. Peña et al. · New England Journal of Medicine · 2001 · 205 citations · Full text